Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Ipsen haemophilia drug commences phase III testing

Ipsen haemophilia drug commences phase III testing

19th November 2010

Ipsen has announced that OBI-1, a collaboratively-developed therapy for haemophilia A, has commenced phase III clinical development.

The company's development partner Inspiration Biopharmaceuticals has begun treating patients in the first of two planned phase III studies of the intravenous
recombinant porcine factor VIII drug, in order to establish its efficacy against serious bleeding episodes.

Inspiration is taking responsibility for the clinical development and commercialisation of the product, under the terms of the agreement signed with Ipsen in January 2010.

As a result of the commencement of the phase III trial, Ipsen has subscribed to a $50 million (31.1 million pounds) newly-issued convertible note by Inspiration, meaning it now owns a 34 percent stake in the company.

Jean-Luc Belingard, chairman and chief executive officer of Ipsen, said: "The advancement of OBI-1 development paves the way towards radical improvement in the therapeutic armamentarium available to the medical practice within the coming years."

Last month, Ipsen published its financial results for the third quarter of 2010, reporting a year-on-year sales growth of 12.4 percent.ADNFCR-8000103-ID-800245743-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.